MYORG

Across TCGA pan-cancer cohorts, MYORG mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYORG data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYORG mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MYORG expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where MYORG mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.823	0.231	<.001	47	view →
LSCC	DFS	Tertile	All	0.887	0.972	.020	7	view →
PDAC	DFS	Quartile	III,IV	0.759	0.304	.024	2	view →
LUAD	DFS	Median	III,IV	0.868	0.634	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYORG–CCRCC (DFS)

Open the CCRCC breakdown →